BCX 14

Drug Profile

BCX 14

Latest Information Update: 19 Apr 1996

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator BioCryst Pharmaceuticals
  • Developer BioCryst Pharmaceuticals; Novartis
  • Class Immunotherapies
  • Mechanism of Action Immunosuppressants; Purine nucleoside phosphorylase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Diabetes mellitus; Rheumatoid arthritis; Systemic lupus erythematosus; Transplant rejection

Most Recent Events

  • 19 Apr 1996 Immunological Disorders section added to drug profile.
  • 19 Apr 1996 Discontinued-Preclinical for Systemic lupus erythematosus in Switzerland (Unknown route)
  • 19 Apr 1996 Discontinued-Preclinical for Systemic lupus erythematosus in USA (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top